Daclatasvir 13C2D6
| Product Name | Daclatasvir 13C2D6 |
|---|---|
| Alternate Names | Daclatasvir Stable Isotopes, Stable Isotopes of Daclatasvir |
| CAT No. | CS-O-11957 |
| CAS No. | 1009119-64-5(Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 746.90 g/mol |
| Mol. For. | C₃₈¹³C₂H₄₄D₆N₈O₆ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Daclatasvir |
| Purity | 95% |
| Therapeutic | Antiretroviral / Anti-HIV |
| Smileys | O=C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@H](CCC6)N6C([C@H](C(C)C)NC(O[13C]([2H])([2H])[2H])=O)=O)N5)C=C4)C=C3)N2)CCC1)[C@H](C(C)C)NC(O[13C]([2H])([2H])[2H])=O |
| Canonical Smiles | CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC |
| InchIKey | FKRSSPOQAMALKA-CUPIEXAXSA-N |
| Inchl | InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1 |
| IUPAC | methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Daclatasvir 13C2D6 is a potent antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. This drug is a deuterated form of daclatasvir, which is a direct-acting antiviral drug that inhibits the non-structural protein 5A (NS5A) of HCV. It is manufactured by Bristol-Myers Squibb under the brand name Daklinza.
Daclatasvir 13C2D6 is available in tablet form and is administered orally. The recommended dose is 60mg once daily for 12 weeks in combination with other antiviral medications such as sofosbuvir or ribavirin. It is important to note that daclatasvir 13C2D6 should not be used as monotherapy as it may lead to the development of drug-resistant strains of HCV.
Chemically, daclatasvir 13C2D6 is a deuterated form of daclatasvir, which means that some of the hydrogen atoms in the drug molecule have been replaced with deuterium atoms. This modification does not alter the drug's mechanism of action or efficacy but increases its half-life and reduces its metabolism. This results in higher plasma concentrations, allowing for greater antiviral activity and reduced dosing frequency.
In conclusion, daclatasvir 13C2D6 is a highly effective medication for the treatment of chronic HCV infection. Its deuterated form provides advantages in terms of pharmacokinetics and dosing frequency. However, it should only be used in combination with other antiviral medications and under the supervision of a healthcare professional.
Get an Instant Quote
Related Compounds
Daclatasvir Diethyl Ester D10 | Daclatasvir D6 |